WENDY KEITEL to Humans
This is a "connection" page, showing publications WENDY KEITEL has written about Humans.
Connection Strength
0.643
-
Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
Score: 0.021
-
Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
Score: 0.020
-
Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine. 2020 07 14; 38(33):5355-5363.
Score: 0.018
-
An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
Score: 0.018
-
Searching for Improved Flu Vaccines-The Time Is Now. J Infect Dis. 2020 01 01; 221(1):1-4.
Score: 0.017
-
Influenza Vaccines After 7 Decades: Still on the Learning Curve. J Infect Dis. 2019 09 13; 220(8):1240-1242.
Score: 0.017
-
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
Score: 0.017
-
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019 08 23; 37(36):5161-5170.
Score: 0.017
-
Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine. 2019 09 03; 37(37):5535-5543.
Score: 0.016
-
Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 12 18; 36(52):8054-8061.
Score: 0.016
-
Challenges Remain for Influenza Vaccination of Children. J Infect Dis. 2016 11 15; 214(10):1470-1472.
Score: 0.014
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
Score: 0.013
-
Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here? J Infect Dis. 2016 Apr 15; 213(8):1211-3.
Score: 0.013
-
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons =18 Years Old. J Infect Dis. 2015 Aug 15; 212(4):552-61.
Score: 0.012
-
Influenza A(H5N1) vaccines: are we better prepared for the next pandemic? J Infect Dis. 2014 Jan 01; 209(1):1-3.
Score: 0.011
-
Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen. BMC Infect Dis. 2013 Jun 19; 13:276.
Score: 0.011
-
Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177.
Score: 0.011
-
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
Score: 0.010
-
Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12.
Score: 0.010
-
Intanza(?): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010 Dec; 9(12):1399-409.
Score: 0.009
-
Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
Score: 0.009
-
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
Score: 0.009
-
Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11; 28(2):379-85.
Score: 0.008
-
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010 Jan 08; 28(3):840-8.
Score: 0.008
-
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44.
Score: 0.008
-
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11.
Score: 0.008
-
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009 Nov 05; 27(47):6642-8.
Score: 0.008
-
Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:323-44.
Score: 0.008
-
Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol. 2009; 333:431-51.
Score: 0.008
-
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 01; 198(9):1309-16.
Score: 0.008
-
Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis. 2008 Oct 01; 198(7):1016-8.
Score: 0.008
-
Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008 Aug; 7(6):713-9.
Score: 0.008
-
Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008 Mar; 7(2):241-7.
Score: 0.008
-
Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol. 2007 Oct; 7(5):484-90.
Score: 0.007
-
Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine. Expert Rev Vaccines. 2006 Aug; 5(4):417-30.
Score: 0.007
-
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
Score: 0.007
-
Postnatal Zika and Dengue Infection and their Effects on Neurodevelopment Among Children Living in Rural Guatemala. Pediatr Infect Dis J. 2025 Apr 01; 44(4):290-298.
Score: 0.006
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
Score: 0.006
-
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 08 11; 228(3):287-298.
Score: 0.006
-
A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
Score: 0.005
-
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. Lancet Infect Dis. 2023 04; 23(4):484-495.
Score: 0.005
-
Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. PLoS Negl Trop Dis. 2022 11; 16(11):e0010480.
Score: 0.005
-
Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy. Semin Pediatr Infect Dis. 2002 Apr; 13(2):112-9.
Score: 0.005
-
Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis. 2001 Jan 15; 183(2):329-332.
Score: 0.005
-
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019 12 13; 68(4):1-14.
Score: 0.004
-
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 1999 Oct 14; 18(5-6):531-9.
Score: 0.004
-
A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999 Aug; 180(2):397-403.
Score: 0.004
-
Cellular and acellular pertussis vaccines in adults. Clin Infect Dis. 1999 Jun; 28 Suppl 2:S118-23.
Score: 0.004
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
Score: 0.004
-
Acellular pertussis vaccines in adults. Infect Dis Clin North Am. 1999 Mar; 13(1):83-94, vi.
Score: 0.004
-
Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614.
Score: 0.004
-
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
Score: 0.004
-
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997 Jul; 15(10):1114-22.
Score: 0.004
-
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
Score: 0.004
-
Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
Score: 0.003
-
Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine. 2016 07 19; 34(33):3796-802.
Score: 0.003
-
Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. Clin Vaccine Immunol. 2016 Apr; 23(4):326-38.
Score: 0.003
-
Hepatitis delta virus: an important human pathogen. Clin Infect Dis. 1996 Mar; 22(3):605.
Score: 0.003
-
Severe paroxysmal coughing and pleuritic pain in an adult. Hosp Pract (1995). 1995 Dec 15; 30(12):65-7.
Score: 0.003
-
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
Score: 0.003
-
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
Score: 0.003
-
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
Score: 0.003
-
Pertussis in adolescents and adults: time to reimmunize? Semin Respir Infect. 1995 Mar; 10(1):51-7.
Score: 0.003
-
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis. 2015 Aug 15; 212(4):525-30.
Score: 0.003
-
Diurnal variation in responses to influenza vaccine. Chronobiol Int. 1995 Feb; 12(1):28-36.
Score: 0.003
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.003
-
High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct; 32(10):2468-73.
Score: 0.003
-
Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine. 2014 Jun 12; 32(28):3548-54.
Score: 0.003
-
Variability in infectivity of cold-adapted recombinant influenza virus vaccines in humans. J Infect Dis. 1994 Feb; 169(2):477.
Score: 0.003
-
Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine. 1994; 12(3):195-9.
Score: 0.003
-
Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28.
Score: 0.003
-
Assessing agreement of repeated binary measurements with an application to the CDC's anthrax vaccine clinical trial. Int J Biostat. 2013 Jul 27; 9(1).
Score: 0.003
-
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15; 208(4):559-63.
Score: 0.003
-
Investigators' perspectives on translating human microbiome research into clinical practice. Public Health Genomics. 2013; 16(3):127-33.
Score: 0.003
-
Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis. 1993 Feb; 167(2):305-11.
Score: 0.003
-
Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 1993; 11(9):909-13.
Score: 0.003
-
The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J. 2013 Mar; 27(3):1012-22.
Score: 0.003
-
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine. 2012 Dec 17; 31(1):190-5.
Score: 0.003
-
Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial. Vaccine. 2012 Aug 31; 30(40):5875-9.
Score: 0.003
-
Perspectives on human microbiome research ethics. J Empir Res Hum Res Ethics. 2012 Jul; 7(3):1-14.
Score: 0.003
-
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis. 2011 Sep 15; 204(6):854-63.
Score: 0.002
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.002
-
Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
Score: 0.002
-
Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis. 1990 Jan; 161(1):22-6.
Score: 0.002
-
Antibody quantity versus quality after influenza vaccination. Vaccine. 2009 Oct 23; 27(45):6358-62.
Score: 0.002
-
Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
Score: 0.002
-
Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
Score: 0.002
-
Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect Immun. 2009 May; 77(5):2030-5.
Score: 0.002
-
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008 Dec 08; 168(22):2405-14.
Score: 0.002
-
Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43.
Score: 0.002
-
Domain specificity of the human antibody response to Bacillus anthracis protective antigen. Vaccine. 2008 Jul 29; 26(32):4041-7.
Score: 0.002
-
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29; 26(32):4057-61.
Score: 0.002
-
Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol. 1988 Feb; 127(2):353-64.
Score: 0.002
-
Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7". Vaccine. 2007 Oct 16; 25(42):7285-7.
Score: 0.002
-
Paratope diversity in the human antibody response to Bacillus anthracis protective antigen. Mol Immunol. 2008 Jan; 45(2):338-47.
Score: 0.002
-
Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respir Viruses. 2007 Jul; 1(4):147-56.
Score: 0.002
-
A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
Score: 0.002
-
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
Score: 0.002
-
Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006 Jul 15; 43(2):151-7.
Score: 0.002
-
Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine. 2006 Aug 14; 24(33-34):5950-9.
Score: 0.002
-
Influenza: its control in persons and populations. J Infect Dis. 1986 Mar; 153(3):431-40.
Score: 0.002
-
Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin. 2005 Nov-Dec; 1(6):239-44.
Score: 0.002
-
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005 Oct 13; 353(15):1555-63.
Score: 0.002
-
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 02; 352(22):2271-84.
Score: 0.002
-
Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005 Feb 03; 23(11):1414-25.
Score: 0.002
-
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis. 2004 Dec 01; 39(11):1715-8.
Score: 0.002
-
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004 Aug 01; 190(3):535-44.
Score: 0.001
-
Healthy elderly people lack neutrophil-mediated functional activity to type V group B Streptococcus. J Am Geriatr Soc. 2004 Jan; 52(1):46-50.
Score: 0.001
-
Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2003 Nov 01; 37(9):1244-9.
Score: 0.001
-
Multiple Epstein-Barr virus infections in healthy individuals. J Virol. 2003 Jun; 77(11):6546-50.
Score: 0.001
-
The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis. 2003 May 15; 187(10):1571-80.
Score: 0.001
-
Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003 Apr 11; 17(6):801-7.
Score: 0.001
-
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun. 2002 Mar; 70(3):1417-21.
Score: 0.001
-
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002 Jan 15; 20(7-8):1099-105.
Score: 0.001
-
Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults. Infect Immun. 2000 Dec; 68(12):7175-9.
Score: 0.001
-
Improvement of inactivated influenza virus vaccines. J Infect Dis. 1997 Aug; 176 Suppl 1:S38-44.
Score: 0.001
-
Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J Infect Dis. 1996 Feb; 173(2):453-6.
Score: 0.001
-
Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine. 1995 Dec; 13(18):1799-803.
Score: 0.001
-
Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
Score: 0.001
-
Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. Am J Epidemiol. 1991 Feb 01; 133(3):296-304.
Score: 0.001
-
Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults. Vaccine. 1990 Jun; 8(3):217-24.
Score: 0.001
-
Immunoassay for serologic diagnosis of influenza type A using recombinant DNA produced nucleoprotein antigen and monoclonal antibody to human IgG. J Med Virol. 1989 Jan; 27(1):25-30.
Score: 0.001
-
Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children. J Virol. 1984 Dec; 52(3):828-32.
Score: 0.000